Phantom Neuro is a technology company.
Phantom Neuro has raised $28.0M across 3 funding rounds.
Key people at Phantom Neuro.
Phantom Neuro has raised $28.0M in total across 3 funding rounds.
Key people at Phantom Neuro.
Phantom Neuro is a neurotechnology company headquartered in Austin, Texas, developing Phantom X, a minimally invasive muscle-machine interface that captures muscle signals for intuitive control of robotic prosthetics, exoskeletons, and other devices[1][2][3][5]. It serves primarily amputees and individuals with limb differences or motor impairments, solving the problem of unnatural, cumbersome prosthetic control by enabling real-time, natural movement restoration—achieving up to 94% gesture accuracy and 85% hand/wrist functionality with minimal calibration[1][4][6]. The company offers clinical/preclinical testing services and targets expansion into elderly mobility aids and human augmentation, backed by a $19M Series A led by Ottobock in 2025, with strong growth via partnerships, a patient registry, and studies like ASCENT demonstrating superior performance over surface sensors[2][6][7].
Phantom Neuro emerged as a spinout from Johns Hopkins University School of Medicine, founded around 2022-2023 by Connor Glass, M.D., who serves as CEO with a background blending neuroscience, surgery, and a mission to restore control for those with disabilities[1][6][7]. Glass's idea stemmed from advances in neuroscience, AI, robotics, and minimally invasive surgery, aiming to create "natural extensions of the human body" beyond traditional prosthetics; in just three years, the company progressed from lab concepts to clinical studies like ASCENT and a $19M Series A in April 2025 led by Ottobock[2][6]. Pivotal early traction included funding from Blackrock Neurotech, Breakout Ventures, Draper Associates, LionBird Ventures, and Time BioVentures, plus an advisory board from CTRL-Labs, DARPA, Johns Hopkins, and Precision Neuro; the launch of a patient registry in late 2025 further accelerated community engagement[7].
Phantom Neuro rides the convergence of neurotechnology, AI-driven robotics, and human augmentation, addressing a massive market of ~2M US amputees and 50M elderly over 65 amid rising demand for intuitive assistive tech[2][3][8]. Timing is ideal post-2025 funding boom, fueled by MedTech investments (e.g., Ottobock's lead) and regulatory paths for outpatient implants, countering limitations of EMG surface tech or invasive neural interfaces[1][2][6]. It influences the ecosystem by partnering with prosthetics leaders, providing testing services, and opening registries to build clinician/amputee networks—paving for "sci-fi" prosthetics that surpass biological limbs, enhancing independence, mental health, and longevity[4][5][7].
Phantom Neuro is primed for market entry via accelerated clinical trials and Ottobock synergy, with Phantom X commercialization likely in 2026-2027, expanding from prosthetics to exoskeletons and augmentation[2][6]. Trends like AI precision medicine, aging populations, and robotics integration will propel growth, potentially evolving influence toward dominant human-machine interfaces that redefine mobility. This positions Phantom Neuro to turn physical limits into enhanced capabilities, fulfilling its mission where assistive devices truly extend the human body[3][4].
Phantom Neuro has raised $28.0M in total across 3 funding rounds.
Phantom Neuro's investors include E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners.
Phantom Neuro has raised $28.0M across 3 funding rounds. Most recently, it raised $19.0M Series A in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $19.0M Series A | E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners | |
| Sep 1, 2022 | $6.0M Seed | E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners | |
| Mar 1, 2022 | $3.0M Seed | E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners |
